Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.

Published in: European journal of drug metabolism and pharmacokinetics (2019)

The developed population pharmacokinetic model adequately described the disposition of pyrazinamide and pyrazinoic acid and can be useful for dose determination of pyrazinamide in patients with MDR-TB.

Keyphrases

mycobacterium tuberculosis
drug resistant
multidrug resistant
acinetobacter baumannii
pulmonary tuberculosis
emergency department
hepatitis c virus
molecularly imprinted
solid phase extraction
mass spectrometry
human immunodeficiency virus
adverse drug
electronic health record